日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

三阴性原发性骨髓纤维化:表型、基因型和预后的比较分析

Bashir, Yassin A; Abdelrheem, Ahmed A; Abdelmagid, Maymona; Reichard, Kaaren K; He, Rong; Zepeda Mendoza, Cinthya J; Pardanani, Animesh; Gangat, Naseema; Tefferi, Ayalew

NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance

骨髓纤维化中的NFκB/IL-6/JAK2/STAT通路是一个关键的脆弱点,可作为靶点,并与JAK2抑制剂治疗耐药性相关。

Bian, Huiqin; Gangat, Naseema; Shen, Na; Pang, Jiuxia; Wald, David; Tse, William; Tefferi, Ayalew; Yan, Fei; Liu, Shujun

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

慢性粒单核细胞白血病中TET2基因突变数量(1个、2个或≥3个):共突变模式及其在包括BLAST-mol和CPSS-mol在内的现代预后模型中的预后意义

Yousuf, Muhammad; Fathima, Saubia; Alsugair, Ali Khalid A; Wu, Samuel J; Abdelmagid, Maymona G; Patel, Shraddha P; Faldu, Priyansh C; Abdelaziz, Rania M; Csizmar, Clifford M; Mangaonkar, Abhishek A; Zepeda Mendoza, Cinthya J; Reichard, Kaaren K; Viswanatha, David S; He, Rong; Pardanani, Animesh; Gangat, Naseema; Patnaik, Mrinal S; Tefferi, Ayalew

A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns

慢性粒单核细胞白血病一线治疗策略的回顾性分析:对生存率和反应模式的影响

Yousuf, Muhammad; Faldu, Priyansh; Abdelmagid, Maymona; Aperna, Fnu; Fathima, Saubia; Alsugair, Ali Khalid A; Csizmar, Clifford M; Lasho, Terra L; Mangaonkar, Abhishek A; Reichard, Kaaren K; He, Rong; Pardanani, Animesh; Gangat, Naseema; Patnaik, Mrinal M; Tefferi, Ayalew

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

TP53突变型髓系肿瘤中5号染色体畸变的特征分析(原始细胞≥5%):一项国际TP53研究者网络(iTiN)研究

Yasin, Irfan; Stengel, Anna; Shao, Haipeng; Kaur, Amandeep; Mason, Emily F; Patwardhan, Pranav P; Bailey, Nathanael G; Ghosh, Sharmila; Inamdar, Kedar V; Patel, Anand A; Pandiri, Madhavi; Zhang, Jingjing; Sojitra, Payal; Tariq, Hamza; Pan, Zenggang; Wiredja, Danica; Wang, Peng; Tjota, Melissa Y; Segal, Jeremy P; Chang, Hong; Sallman, David A; Arber, Daniel A; Tefferi, Ayalew; Badar, Talha; Perry, Anamarija M; Haferlach, Claudia; Lager, Angela M; Venkataraman, Girish

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A

染色体碎裂相关21号染色体扩增通过DYRK1A的靶向过表达调控MPN向急变期转化

Charlotte K Brierley #,Bon Ham Yip #,Giulia Orlando #,Jeremy Wen,Sean Wen,Harsh Goyal,Max Levine,G Maria Jakobsdottir,Avraam Tapinos,Alex J Cornish,Antonio Rodriguez-Romera,Alba Rodriguez-Meira,Matthew Bashton,Angela Hamblin,Sally Ann Clark,Joseph C Hamley,Olivia Fox,Madalina Giurgiu,Jennifer O'Sullivan,Lauren Murphy,Assunta Adamo,Aude Anais Olijnik,Anitria Cotton,Emily Hendrix,Shilpa Narina,Shondra M Pruett-Miller,Amir Enshaei,Claire Harrison,Mark Drummond,Steven Knapper,Ayalew Tefferi,Iléana Antony-Debré,James Davies,Anton G Henssen,Supat Thongjuea,David C Wedge,Stefan N Constantinescu,Elli Papaemmanuil,Bethan Psaila,John D Crispino,Adam J Mead

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification

WHO“经典骨髓增生性肿瘤”诊断标准的演变与国际共识分类的比较

Thiele, Jürgen; Kvasnicka, Hans Michael; Gianelli, Umberto; Arber, Daniel A; Tefferi, Ayalew; Vannucchi, Alessandro M; Barbui, Tiziano; Orazi, Attilio

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

维奈托克治疗急性髓系白血病的疗程:7 天 vs 14 天 vs 21 天 vs 28 天

Gangat, Naseema; Tefferi, Ayalew

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

在独立的国际队列中验证世界卫生组织和国际共识分类指南第五版中TP53突变型髓系肿瘤的分类标准

Shah, Mithun Vinod; Hung, Kevin; Baranwal, Anmol; Wechalekar, Gauri; Al-Kali, Aref; Toop, Carla R; Greipp, Patricia; Kutyna, Monika M; Matin, Aasiya; Ladon, Dariusz; Saliba, Antoine; Chen, Dong; Begna, Kebede; Brown, Anna; Rud, Danielle; Litzow, Mark R; Hogan, William J; Bardy, Peter; Badar, Talha; Kumar, Sharad; Yeung, David T; Patnaik, Mrinal M; Foran, James M; He, Rong; Gangat, Naseema; Hefazi, Mehrdad; Scott, Hamish S; Arana Yi, Cecilia Y; Alkhateeb, Hassan; Mangaonkar, Abhishek A; Thomas, Daniel; Hahn, Christopher N; Orazi, Attilio; Arber, Daniel A; Kok, Chung Hoow; Tefferi, Ayalew; Hiwase, Devendra

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

莫美替尼治疗未接受过JAK2抑制剂治疗的骨髓纤维化:利弊分析

Gangat, Naseema; Tefferi, Ayalew